PHILADELPHIA - Brian Strom, MD, Chair and Professor of Biostatistics and Epidemiology and Director of the Center for Clinical Epidemiology & Biostatistics, has been named Editor-in-Chief of Pharmacoepidemiology and Drug Safety, the official journal of the International Society for Pharmacoepidemiology, starting September 1.
“As Editor-in-Chief, my goals are to develop the journal into the premier journal for the field in the world,” says Strom. His duties include determining policy and papers accepted to the journal. He will hold the position until December of 2012, renewable thereafter.
The journal publishes papers on drug safety, pharmaceutical risk management, and the new field of comparative effectiveness research. Particular areas of interest include: design, results, analysis and interpretation of post-marketing surveillance and other studies looking at specific drugs, populations and outcomes; methods for detection and evaluation of drug-associated adverse events; assessments of risk and benefit in drug therapy; patterns of drug utilization; and the relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines.
Strom's clinical and research training is in general internal medicine, clinical pharmacology, and epidemiology. He has authored over 500 publications, including peer-reviewed articles, editorials, reviews, chapters, and books.
Sean Hennessy, PharmD, PhD, Associate Professor of Epidemiology and Pharmacology and Director of the Ambulatory Drug Use & Effects Program will be assuming the position of Regional Editor for the Americas for the journal, also starting September 1. Hennessy’s primary field of interest is pharmacoepidemiology. He is currently leading National Institutes of Health-funded studies on drug-induced sudden death and ventricular arrhythmia, and on the clinical importance of drug-drug interactions.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.